Login / Signup

The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM).

Hayder M Al-KuraishyAli I Al-GareebHebatallah M SaadGaber El-Saber Batiha
Published in: Inflammopharmacology (2023)
Fibroblast growth factor 21 (FGF21) is a peptide hormone mainly synthesized and released from the liver. FGF21 acts on FGF21 receptors (FGFRs) and β-Klotho, which is a transmembrane co-receptor. In type 2 diabetes mellitus (T2DM), inflammatory disorders stimulate the release of FGF21 to overcome insulin resistance (IR). FGF21 improves insulin sensitivity and glucose homeostasis. Metformin which is used in the management of T2DM may increase FGF21 expression. Accordingly, the objective of this review was to clarify the metformin effect on FGF21 in T2DM. FGF21 level and expression of FGF2Rs are dysregulated in T2DM due to the development of FGF21 resistance. Metformin stimulates the hepatic expression of FGF21/FGF2Rs by different signaling pathways. Besides, metformin improves the expression of β-Klotho which improves FGF21 sensitivity. In conclusion, metformin advances FGF21 signaling and decreases FGF21 resistance in T2DM, and this might be an innovative mechanism for metformin in the enhancement of glucose homeostasis and metabolic disorders in T2DM patients.
Keyphrases
  • poor prognosis
  • insulin resistance
  • type diabetes
  • oxidative stress
  • signaling pathway
  • climate change
  • metabolic syndrome
  • adipose tissue
  • high fat diet
  • risk assessment
  • binding protein
  • cell proliferation